tissue of rat adjuvant-induced arthritis by Short Communication et al.
Short communication
Triptolide inhibits CCR5 expressed in synovial
tissue of rat adjuvant-induced arthritis
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Abstract:
Triptolidehasbeenclinicallyusedtotreatpatientswithrheumatoidarthritis,inwhichchemokinereceptorsplayanimportantrolein
immune and inflammatory responses. To investigate the effect of triptolide on CCR5, we used complete Freund’s adjuvant to pro-
duceadjuvant-inducedarthritis(AIA)inrats.OurdatashowthatbothCCR5mRNAandproteinlevelsinsynovialtissueofratswith
AIAare significantly higher than those in normal rats. Triptolide can significantly inhibit rat AIA-induced overexpression of CCR5
atbothmRNAandproteinlevels.Theseresultsmaycontributetobetterunderstandingofthetherapeuticeffectsoftriptolideinrheu-
matoid arthritis.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
condition that affects multiple joints and results in the
accumulation of leukocytes within the synovial tissue
(ST) and synovial fluid (SF). The pathogenesis of RA
is still largely unknown but leukocytes and their prod-
ucts play an important role in the development of in-
flammation, joint destruction and pain [16]. The at-
traction of leukocytes into the joints is controlled by
chemokines. Chemokine activity is dependent on the
presence of an interaction with chemokine receptors
on the leukocyte surface. Indeed, chemokines and their
receptors are involved together in the development
and perpetuation of inflammation [3]. Chemokine re-
ceptors have a regulatory effect on the maturation and
traffic of leukocytes, and they are implicated in several
disease states, including RA [10]. Of particular inter-
est regarding therapeutic intervention in RA is CCR5,
the receptor for RANTES/CCL5, MIP-1/CCL3, and
MIP-1/CCL4. CCR5 showed strong expression on
ST fibroblasts and ST T lymphocytes in RA [15].
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present on mononuclear cells in SF from patients with
RA[4, 9].
Tripterygium wilfordii Hook. F (TWHF), a perennial
vine-like member of the Celastraceae plant family,
has been reported to show efficacy in the treatment of
RA, psoriatic arthritis, and systemic lupus erythema-
tosus. Triptolide, a highly oxygenated diterpenoid
triepoxide, as an active component in TWHF, has
been identified to possess potent anti-inflammatory
and immunosuppressive activities in patients and ani-
mals with a variety of inflammatory and autoimmune
diseases, including RA[5, 11]. However, no data about
the effect of triptolide on CCRs are available to date.
The present study was designed to explore the effect
of triptolide on the expression of CCR5 in ST of rat
adjuvant-induced arthritis (AIA), which is a widely
used experimental model for studying the pathogene-
sis of human RA.
Materials and Methods
Animals
Female adult Sprague-Dawley rats (200 ± 20 g) were
used throughout the study. Animals were kept in
cages (four animals per cage) at a room with con-
trolled temperature (23 ± 2°C) and on a 12-h light-
dark cycle. Water and food were given ad libitum.
The local animal ethics committee has approved all
experimental procedures described below.
Drug treatment
After being anesthetized, rats were immunized subcu-
taneously at the palmar surface of the right hind paw
on day 0 with 0.1 ml of 10 mg/ml Mycobacterium tu-
berculosis in incomplete Freund’s adjuvant for the in-
duction of arthritis, while rats in normal group were
injected with a single dose of 0.1 ml of physiological
saline. Triptolide was dissolved in physiological sa-
line containing 4% 1,2-propylene glycol and applied
intraperitoneally once a day. Two treatment groups re-
ceived an injection of 0.1 mg/kg or 0.2 mg/kg of trip-
tolide on day 14 after arthritis induction and main-
tained until day 20. Two control groups received an
equal amount of 4% 1,2-propylene glycol saline solu-
tion.
Immunohistochemistry
On day 21, the animals were sacrificed for immuno-
histochemical analysis. Right hind ankle joints were
fixed in 10% buffered formalin, followed by treatment
with 8% nitric acid solution for decalcification, dehy-
drated, cleared and embedded in paraffin. Immuno-
staining was performed on ST sections (4 m), using
SABC kits (Boster, China) and 3,3’-diaminobenzidine
(DAB) as a chromogen, followed by counterstaining
with hematoxylin. Sections were incubated overnight
at 4°C with primary antibody, a rabbit anti-rat CCR5
polyclonal antibody (1:150) (Boster, China), while
PBS was used as a negative control.
After immunohistochemical staining, all sections
were examined by using a LOGENE-I PAS9000
computer-assisted color video image analysis system
(LOGENE, China). Measurement of the integrated
optical density (IOD, proportional to the total amount
of protein staining) was made by an observer who was
unaware of the order of sections.
Reverse transcription-polymerase chain reac-
tion (RT-PCR)
Total RNAfrom ST of knee joints was extracted using
Trizol reagent (BBI, Canada) according to the manu-
facturer’s instructions. First strand cDNA was synthe-
sized using AMV RTase XL reverse transcriptase
(Takara, Japan) at 46°C for 45 min. For PCR, 2 lo f
each cDNA sample was amplified by using Ex Taq
polymerase (Takara, Japan). The primer sequences for
CCR5 were: sense, 5’-CAC CCT GTT TCG CTG
TAG GAA TG-3’; and antisense, 5’-GCA GTG TGT
CAT CCC AAG AGT CTC-3’. Those for GAPDH
were: sense, 5’-TGA TGA CAT CAA GAA GGT
GGT GAA G-3’; and antisense, 5’-TCC TTG GAG
GCC ATG TAG GCC AT-3’. The sizes of amplified
products were 214 bp for CCR5 and 240 bp for
GAPDH. Amplification conditions were denaturation
at 94°C for 1 min, annealing for 1 min at 62°C for
CCR5 and 60°C for GAPDH, and extension at 72°C
for 1 min for 30 cycles. Amplification products (2.5 l
each) were electrophoretically separated on 1.5% aga-
rose gels and stained with ethidium bromide and ana-
lyzed by using a Gel Doc 2000 analysis system (Bio-
RAD, USA).
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The experimental results were expressed as the mean
±S Do fn rats per group. SPSS was used for data analy-
sis. Statistical analysis was evaluated by Dunnett’s t-test,
with the level of significance chosen at p < 0.05.
Results
Immunohistochemical study of CCR5 in syno-
vial tissue
CCR5 could be detected in ST in all groups. Normal
rat ST exhibited weak constitutive expression of
CCR5. The synovial lining layer and synovial sublin-
ing region were diffusely immunoreactive for CCR5.
CCR5 was also localized in the vascular regions
(Fig. 1). Slides were negative when the primary anti-
body was omitted (data not shown). In general, CCR5
was up-regulated at the protein level on ST cells in
AIA rats and significantly decreased in both triptolide
treatment groups (Fig. 1).
Expression of CCR5 mRNA in synovial tissue
To strengthen the results from immunohistochemical
staining, we next performed RT-PCR to examine
CCR5 gene expression in ST. CCR5 mRNA was ex-
pressed in ST of normal rats, but was up-regulated in
ST of AIA rats compared with that of normal rats.
Triptolide exhibited an inhibitory effect on CCR5
mRNA expression, while this effect was most evident
after the dose of 0.2 mg/kg of triptolide (Fig. 2).
Discussion
In this study, we induced AIA and harvested rat joints
after injection of triptolide or vehicle. CCR5 was ana-
lyzed by immunohistochemistry at protein level and
RT-PCR at mRNAlevel. To our knowledge, this is the
first study to demonstrate that triptolide can inhibit
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The migration of leucocytes from the bloodstream
into the inflammation sites is a dynamic process con-
sisting of multiple steps involving adhesion molecules
and chemotactic factors. Chemokines regulate the
traffic of leucocytes by inducing cell motility and by
activating adhesion molecules. Chemokine receptors
allow leucocytes to sense chemokine gradients, there-
by directing these cells into tissue compartments. As
a result, the interaction of chemokines and chemokine
receptors plays an important role in regulating leuco-
cyte traffic within the immune system. Since che-
mokines and their receptors have been suggested to be
potential targets in the therapy of RA [1], a better
characterization of the functional relevance of the
CCR5 receptor to cell migration in response to syno-
vial chemokines is warranted. Indeed, it has recently
been reported that accumulation of CCR5-positive T
lymphocytes is seen in the inflamed synovium and in
the SF of RA, and seems to be of importance in the re-
cruitment of Th1 lymphocytes into the joint [8, 15].
CCR5 expression was also significantly elevated on
synovial lining cells, macrophages, and endothelial
cells in ST of AIA rats [2, 13]. An array-based analy-
sis of not-yet-inflamed joints in mice with autoim-
mune arthritis also identified CCR5 as one of the most
highly up-regulated genes [7]. The interaction of
CCR5 with its ligands is crucial for the development
and severity of RA, on the basis of the recent demon-
stration that RA activity correlates with the polymor-
phism of CCR5 [20].
Murine experimental arthritis can be partially ame-
liorated by blocking CCR5 using selective receptor
antagonists. A recent study showed that the collagen-
induced arthritis (CIA) phenotype in CCR5-deficient
mice was similar to that in wild-type mice [12].
A CCR5 nonpeptide antagonist, when used preven-
tively, inhibited mouse CIA and migration of leuko-
cytes to the joints [19]. Blocking of CCR5 with Met-
RANTES in rat AIAresulted in reduced joint destruc-
tion [14]. Furthermore, in a nonhuman primate model
of RA, treatment with a CCR5 antagonist resulted in
clinical improvement of the disease [17]. Taken to-
gether, these findings indicate that CCR5 targeting is
an interesting potential therapeutic approach.
We have reported that treatment with triptolide
from day 14 could effectively reduce the edema of rat
hind paw [18]. It also has been reported that triptolide
can inhibit the expression of MIP-1, MIP-1 and
RANTES, the ligands of CCR5, at both mRNA and
protein levels [6, 18]. Our results demonstrate that
triptolide not only inhibits the production of the
ligands of CCR5, but also CCR5 itself. The inhibition
of CCR5 expression in ST may be explained by
down-regulation of the receptor or decreased migra-
tion of cells expressing the receptor towards the sites
of inflammation, or a combination of both. This inhi-
bition may also contribute to the therapeutic effects of
triptolide in RA.
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